Dose optimisation in antidepressant drug development

International Congress Series

Volumn 1220, Issue C, 2001, Pages 223-245

  Deakin, Bill ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Antidepressants; Depression; Functional magnetics resonance imaging (fMRI); Noradrenaline; Positron emission tomography (PET); Serotonin

Indexed keywords

EID: 74249095204     PISSN: 05315131     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0531-5131(01)00299-0     Document Type: Article

References (66)

1. Kent, J.M, SnaRIs, NaSSAs and NaRIs: new agents for the treatment of depression. Lancet 355 (2000), 503–509.
2. Sanchez, C, Hyttel, J, Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Mol. Neurobiol. 19 (1999), 467–489.
3. Harvey, A.T, Rudolph, R.L, Preskorn, S.H, Evidence of the dual mechanisms of action of venlafaxine. Arch. Gen. Psychiatry 57:5 (2000), 503–509.
4. Puech, A, Montgomery, S.A, Prost, J.F, Solles, A, Briley, M, Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability. Int. Clin. Psychopharmacol. 12:2 (1997), 99–108.
5. Gorman, J.M, Mirtazapine: clinical overview. J. Clin. Psychiatry 60:S17 (1999), 9–13.
6. Feighner, J, Targum, S.D, Bennett, M.E, Roberts, D.L, Kensler, T.T, D'Amico, M.F, Hardy, S.A, A double-blind, placebo-controlled trial of nefazodone in the treatment of patients hospitalized for major depression. J. Clin. Psychiatry 59:5 (1998), 246–253.
7. Deakin, J.F.W, 5HT2 receptors in depression and anxiety. Pharmacol. Biochem. Behav. 29:4 (1988), 819–820.
8. Beique, J.C, Blier, P, de Montigny, C, Debonnel, G, Potentiation by (−)Pindolol of the activation of postsynaptic 5-HT(1A) receptors induced by venlafaxine. Neuropsychopharmacology 23:3 (2000), 294–306.
9. Haddjeri, N, Blier, P, de Montigny, C, Long-term antidepressant treatments result in a tonic activation of forebrain 5HT1A receptors. J. Neurosci. 18:23 (1998), 10150–10156.
10. Delgado, P.L, Price, L.H, Miller, H.L, Salomon, R.M, Licinio, J, Krystal, J.H, Heninger, G.R, Charney, D.S, Rapid serotonin depletion as a provocative challenge test for patients with major depression: relevance to antidepressant action and the neurobiology of depression. Psychopharmacol. Bull. 27 (1991), 321–330.
11. Delgado, P.L, Charney, D.S, Price, L.H, Aghajanian, G.K, Landis, H, Heninger, G.R, Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch. Gen. Psychiatry 47:5 (1990), 411–418.
12. Miller, H.L, Delgado, P.L, Salomon, R.M, Heninger, G.R, Charney, D.S, Effects of alpha-methyl-para-tyrosine (AMPT) in drug-free depressed patients. Neuropsychopharmacology 14:3 (1996), 151–157.
13. Delgado, P.L, Miller, H.L, Salomon, R.M, Licinio, J, Krystal, J.H, Moreno, F.A, Heninger, G.R, Charney, D.S, Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action. Biol. Psychiatry 46:2 (1999), 212–220.
14. Romero, L, Bel, N, Artigas, F, de Montigny, C, Blier, P, Effect of pindolol on the function of pre- and postsynaptic 5-HT1A receptors in vivo microdialysis and electrophysiological studies in the rat brain. Neuropsychopharmacology 15:4 (1996), 349–360.
15. Berman, R.M, Anand, A, Cappiello, A, Miller, H.L, Hu, X.S, Oren, D.A, Charney, D.S, The use of pindolol with fluoxetine in the treatment of major depression: final results from a double-blind, placebo-controlled trial. Biol. Psychiatry 45:9 (1999), 1170–1177.
16. Maes, M, Libbrecht, I, van Hunsel, F, Campens, D, Meltzer, H.Y, Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalised major depressed patients, including those with treatment resistance. J. Clin. Psychopharmacol. 19:2 (1999), 177–182.
17. Perez, V, Gilaberte, I, Faries, D, Alvarex, E, Artigas, F, Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet 349:9065 (1997), 1594–1597.
18. Perez, V, Soler, J, Puigdemont, D, Alvarez, E, Artigas, F, A double-blind, randomised, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Arch. Gen. Psychiatry 56:4 (1999), 375–379.
19. Bordet, R, Thomas, P, Dupuis, B, Effect of pindolol on onset of action of paroxetine in the treatment of major depression: intermediate analysis of a double-blind, placebo-controlled trial. Am. J. Psychiatry 155:10 (1998), 169–174.
20. Moreno, F.A, Gelenberg, A.J, Bachar, K, Delgado, P.L, Pindolol augmentation of treatment-resistant depressed patients. J. Clin. Psychiatry 58:10 (1997), 437–439.
21. Rupniak, N.M, Kramer, M.S, Discovery of the antidepressant and anti-emetic efficacy of substance P receptor (NK1) antagonists. Trends Pharmacol. Sci. 20:12 (1999), 485–490.
22. Nowak, G, Legutko, B, Skolnick, P, Popik, P, Adaptation of cortical NMDA receptors by chronic treatment with specific serotonin reuptake inhibitors. Eur. J. Pharmacol. 342:2–3 (1998), 367–370.
23. Holsboer, F, The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 23:5 (2000), 477–501.
24. Duman, R.S, Malberg, J, Nakagawa, S, D'Sa, C, Neuronal plasticity and survival in mood disorders. Biol. Psychiatry 48:8 (2000), 732–739.
25. Andrew, M, McGuffin, P, Katz, R, Genetic and non-genetic subtypes of major depressive disorder. Br. J. Psychiatry 173 (1998), 523–526.
26. Angst, J, Switch from depression to mania—a record study over decades between 1920 and 1982. Psychopathology 18:2–3 (1985), 140–154.
27. Prien, R.F, Kupfer, D.J, Mansky, P.A, Small, J.G, Tuason, V.B, Voss, C.B, Johnson, W.E, Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders. Report of the NIMH collaborative study group comparing lithium carbonate, imipramine, and a lithium carbonate–imipramine combination. Arch. Gen. Psychiatry 41:11 (1984), 1096–1104.
28. Johnstone, E.C, Deakin, J.F, Lawler, P, Frith, C.D, Stevens, M, McPherson, K, Crow, T.J, The Northwick Park electroconvulsive therapy trial. Lancet 2:8208–8209 (1980), 1317–1320.
29. Parker, G, Roy, K, Hadzi-Pavlovic, D, Pedic, F, Psychotic (delusional) depression: a meta-analysis of physical treatments. J. Affect Disord. 24:1 (1992), 17–24.
30. Simpson, G.M, Lee, J.H, Cuculic, Z, Kellner, R, Two dosages of imipramine in hospitalised endogenous and neurotic depressives. Arch. Gen. Psychiatry 33 (1996), 1093–1102.
31. Bebbington, P.E, Brugha, T, MacCarthy, B, Potter, J, Sturt, E, Wykes, T, Katz, R, McGuffin, P, The camberwell collaborative depression study: I. Depressed probands: adversity and the form of depression. Br. J. Psychiatry 152 (1988), 754–765.
32. Carney, M.W.P, Roth, M, Garside, R.F, The diagnosis of depressive syndromes and the prediction of ECT response. Br. J. Psychiatry 111 (1965), 659–674.
33. Paykel, E.S, Parker, R.R, Rowan, P.R, Rao, B.M, Taylor, C.N, Nosology of atypical depression. Psychol. Med. 13:1 (1983), 131–139.
34. McGrath, P.J, Stewart, J.W, Janal, M.N, Petkova, E, Quitkin, F.M, Klein, D.F, A placebo-controlled study of fluoxetine versus imipramine in the acute treatment of atypical depression. Am. J. Psychiatry 157:3 (2000), 344–350.
35. Abdelmawla, A.H, Langley, R.W, Szabadi, E, Bradshaw, C.M, Comparison of the effects of venlafaxine, desipramine, and paroxetine on noradrenaline- and methoxamine-evoked constriction of the dorsal hand vein. Br. J. Clin. Pharmacol. 48:3 (1999), 345–354.
36. Bitsios, P, Szabadi, E, Bradshaw, C.M, Comparison of the effects of venlafaxine, paroxetine and desipramine on the pupillary light reflex in man. Psychopharmacology (Berlin) 143:3 (1999), 286–292.
37. Porter, R.J, McAllister-Williams, R.H, Young, A.H, Acute effects of venlafaxine and paroxetine on serotonergic transmission in human volunteers. Psychopharmacology (Berlin) 146:2 (1999), 194–198.
38. Grasby, P.M, Imaging strategies in depression. J. Psychopharmacol. 13:4 (1999), 346–351.
39. Malison, R.T, Price, L.H, Berman, R, van Dyck, C.H, Pelton, G.H, Carpenter, L, Sanacora, G, Owens, M.J, Nemeroff, C.B, Rajeevan, N, Baldwin, R.M, Seibyl, J.P, Innis, R.B, Charney, D.S, Reduced brain serotonin transporter availability in major depression as measured by [123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane and single photon emission computed tomography. Biol. Psychiatry 44:11 (1998), 1090–1098.
40. Willeit, M, Praschak-Rieder, N, Neumeister, A, Pirker, W, Asenbaum, S, Vitouch, O, Tauscher, J, Hilger, E, Stastny, J, Brucke, T, Kasper, S, [123I]-beta-CIT SPECT imaging shows reduced brain serotonin transporter availability in drug-free depressed patients with seasonal affective disorder. Biol. Psychiatry 47:6 (2000), 482–489.
41. Tauscher, J, Pirker, W, de Zwaan, M, Asenbaum, S, Brucke, T, Kasper, S, In vivo visualization of serotonin transporters in the human brain during fluoxetine treatment. Eur. Neuropsychopharmacol. 9:1–2 (1999), 177–179.
42. Preskorn, S.H, Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin. Pharmacokinet. 32 (1997), 1–21.
43. Drevets, W.C, Frank, E, Price, J.C, Kupfer, D.J, Holt, D, Greer, P.J, Huang, Y, Gautier, C, Mathis, C, PET imaging of serotonin 1A receptor binding in depression. Biol. Psychiatry 46:10 (1999), 1375–1387.
44. 11C]WAY-100635: effects of depression and antidepressant treatment. Arch. Gen. Psychiatry 57 (2000), 174–180.
45. 11C]WAY-100635. Nucl. Med. Biol. 27 (2000), 509–513.
46. Martinez, D, Mawlawi, O, Hwang, D, Kent, J, Simpson, N, Parsey, R.V, Hashimoto, T, Slifstein, M, Huang, Y, Van Heertum, R, Abi-Dargham, A, Caltabiano, S, Malizia, A, Cowley, H, Mann, J.J, Laruelle, M, Positron emission tomography study of pindolol occupancy of 5-HT(1A) receptors in humans: preliminary analyses. Nucl. Med. Biol. 27:5 (2000), 523–527.
47. Yatham, L.N, Liddle, P.F, Shiah, I.S, Scarrow, G, Lam, R.W, Adam, M.J, Zis, A.P, Ruth, T.J, Brain serotonin2 receptors in major depression: a positron emission tomography study. Arch. Gen. Psychiatry 57:9 (2000), 850–858.
48. Attar-Levy, D, Martinot, J.L, Blin, J, Dao-Castellana, M.H, Crouzel, C, Mazoyer, B, Poirier, M.F, Bourdel, M.C, Aymard, N, Syrota, A, Feline, A, The cortical serotonin2 receptors studied with positron-emission tomography and [18F]-setoperone during depressive illness and antidepressant treatment with clomipramine. Biol. Psychiatry 45:2 (1999), 180–186.
49. Biver, F, Wikler, D, Lotstra, F, Damhaut, P, Goldman, S, Mendlewicz, J, Serotonin 5-HT2 receptor imaging in major depression: focal changes in orbito-insular cortex. Br. J. Psychiatry 171 (1997), 444–448.
50. D'haenen, H, Bossuyt, A, Mertens, J, Bossuyt-Piron, C, Gijsemans, M, Kaufman, L, SPECT imaging of serotonin2 receptors in depression. Psychiatry Res. 45:4 (1992), 227–237.
51. Meyer, J.H, Cho, R, Kennedy, S, Kapur, S, The effects of single dose nefazodone and paroxetine upon 5-HT2A binding potential in humans using [18F]-setoperone PET. Psychopharmacology (Berlin) 144:3 (1999), 279–281.
52. Mann, J.J, Role of the serotonergic system in the pathogenesis of major depression and suicidal behavior. Neuropsychopharmacology 21:2 Suppl. (1999), 99S–105S.
53. Meyer, J.H, Kapur, S, Houle, S, DaSilva, J, Owczarek, B, Brown, G.M, Wilson, A.A, Kennedy, S.H, Prefrontal cortex 5-HT2 receptors in depression: an [18F]setoperone PET imaging study. Am. J. Psychiatry 156:7 (1999), 1029–1034.
54. Yatham, L.N, Liddle, P.F, Dennie, J, Shiah, I.S, Adam, M.J, Lane, C.J, Lam, R.W, Ruth, T.J, Decrease in brain serotonin2 receptor binding in patients with major depression following desipramine treatment: a positron emission tomography study with fluorine-18-labeled setoperone. Arch. Gen. psychiatry 56:8 (1999), 705–711.
55. Peroutka, S.J, Snyder, S.H, Regulation of serotonin2 (5-HT2) receptors labelled with [3H]spiroperidol by chronic treatment with the antidepressant amitriptyline. J. Pharmacol. Exp. Ther. 215:3 (1980), 582–587.
56. Massou, J.M, Trichard, C, Attar-Levy, D, Feline, A, Corruble, E, Beaufils, B, Martinot, J.L, Frontal 5-HT2A receptors studied in depressive patients during chronic treatment by selective serotonin reuptake inhibitors. Psychopharmacology (Berlin) 133:1 (1997), 99–101.
57. Hommer, D, Andreasen, P, Rio, D, Williams, W, Ruttiman, U, Momenan, R, Zametkin, A, Rawlings, R, Linnoila, M, Effects of m-chlorophenylpiperazine on regional brain glucose utilization: a positron emission tomographic comparison of alcoholic and control subjects. J. Neurosci. 17 (1997), 2796–2806.
58. Coull, J.T, Frith, C.D, Dolan, R.J, Frackowiak, R.S, Grasby, P.M, The neural correlates of the noradrenergic modulation of human attention, arousal and learning. Eur. J. Neurosci. 9 (1997), 589–598.
59. Nelson, J.C, Mazure, C.M, Bowers, M.B Jr., Jatlow, P.I, A preliminary, open study, of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch. Gen. Psychiatry 48 (1991), 303–307.
60. I.M. Anderson, Meta-analysis of venlafaxine vs SSRIs. Personal communication.
61. Velten, E Jr., A laboratory task for induction of mood states. Behav. Res. Ther. 6:4 (1968), 473–482.
62. Mayberg, H.S, Liotti, M, Brannan, S.K, McGinnis, S, Mahurin, R.K, Jerabek, P.A, Silva, J.A, Tekell, J.L, Martin, C.C, Lancaster, J.L, Fox, P.T, Reciprocal limbic–cortical function and negative mood: converging PET findings in depression and normal sadness. Am. J. Psychiatry 156:5 (1999), 675–682.
63. Brody, A.L, Saxena, S, Silverman, D.H, Alborzian, S, Fairbanks, L.A, Phelps, M.E, Huang, S.C, Wu, H.M, Maidment, K, Baxter, L.R Jr., Brain metabolic changes in major depressive disorder from pre- to post-treatment with paroxetine. Psychiatry Res. 91:3 (1999), 127–139.
64. Wu, J, Buchsbaum, M.S, Gillin, J.C, Tang, C, Cadwell, S, Wiegand, M, Najafi, A, Klein, E, Hazen, K, Bunney, W.E Jr., Fallon, J.H, Keator, D, Prediction of antidepressant effects of sleep deprivation by metabolic rates in the ventral anterior cingulate and medial prefrontal cortex. Am. J. Psychiatry 156:8 (1999), 1149–1158.
65. Elliott, R, Friston, K.J, Dolan, R.J, Dissociable neural responses in human reward systems. J. Neurosci. 20:16 (2000), 6159–6165.
66. Koepp, M.J, Gunn, R.N, Lawrence, A.D, Cunningham, V.J, Dagher, A, Jones, T, Brooks, D.J, Bench, C.H, Grasby, P.M, Evidence for striatal dopamine release during a video game. Nature 393:6682 (1998), 266–268.